CNST - コンステレ―ション・ファ―マシュ―ティカルズ (Constellation Pharmaceuticals Inc.) コンステレ―ション・ファ―マシュ―ティカルズ

 CNSTのチャート


 CNSTの企業情報

symbol CNST
会社名 Constellation Pharmaceuticals Inc (コンステレ―ション・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Constellation Pharmaceuticals Inc. is a United States-based company which discovers and develops small molecule therapeutics for the treatment of cancer inflammatory/immunologic disorders and other diseases. The Company has two clinical-stage oncology development programs: the first program is evaluating a compound CPI-0610 and the other program is evaluating a compound CPI-1205. CPI-0610 is a small molecule that inhibits the binding of bromodomain and extra terminal (BET) proteins to chromatin. CPI-1205 is a small molecule that inhibits an enzyme Enhancer of Zeste Homolog 2 (EZH2). It is in a Phase I clinical study of CPI-0610 in patients with progressive lymphoma; a Phase I clinical study of CPI-0610 in patients with acute leukemia myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasms; a Phase I clinical study of CPI-0610 in patients with previously treated multiple myeloma and a Phase 1 clinical study of CPI-1205 in patients with lymphoma.   コンステレ―ション・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、異常な遺伝子発現や薬剤耐性に起因するがん患者の治療薬の開発に従事する。同社の医薬品候補CPI-1205は、アンドロゲン受容体シグナル伝達阻害剤と組み合わせた前立腺がんの治療、免疫と組み合わせた固形がんの治療に使用される。本社所在地はマサチュ―セッツ州ケンブリッジ。   
本社所在地 215 First Street Suite 200 Cambridge MA 02142 USA
代表者氏名 Mark A. Goldsmith マークA.ゴールドスミス
代表者役職名 Executive Chairman Venture Partner
電話番号 +1 617-714-0555
設立年月日 39448
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数
url www.constellationpharma.com
nasdaq_url https://www.nasdaq.com/symbol/cnst
adr_tso
EBITDA EBITDA(百万ドル) -45.22600
終値(lastsale) 6.78
時価総額(marketcap) 174373667.4
時価総額 時価総額(百万ドル) 174.88800
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 360.13900
当期純利益 当期純利益(百万ドル) -55.62300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Constellation Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased 8% to $24M. Higher net loss reflects FV Adjustments of Financial Investments decrease from $4.4M (income) to $0K Research and development - Balancing increase of 29% to $18.9M (expense) General and administrative - Balanci increase of 66% to $2.3M (expense).

 CNSTのテクニカル分析


 CNSTのニュース

   Brookline Capital Markets Stick to Their Buy Rating for Constellation Pharmaceuticals By Investing.com  2021/02/27 17:55:00 Investing.com
Brookline Capital Markets Stick to Their Buy Rating for Constellation Pharmaceuticals
   Insider Selling: Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) CFO Sells $235,376.00 in Stock  2021/02/26 10:54:49 Watchlist News
Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) CFO Emma Reeve sold 6,260 shares of the stock in a transaction on Monday, February 22nd. The shares were sold at an average price of $37.60, for a total transaction of $235,376.00. Following the completion of the sale, the chief financial officer now directly owns 4,010 shares of the company’s stock, […]
   RBC Capital Stick to Their Buy Rating for Constellation Pharmaceuticals By Investing.com  2021/02/26 01:47:19 Investing.com
RBC Capital Stick to Their Buy Rating for Constellation Pharmaceuticals
   H.C. Wainwright Stick to Their Buy Rating for Constellation Pharmaceuticals By Investing.com  2021/02/25 11:38:21 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Constellation Pharmaceuticals
   Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation  2021/01/25 17:32:58 Benzinga
After strong performance in 2020, biopharma stocks are expected to continue their winning run in the new year. Among the companies in the space, analysts at BMO Capital Markets are particularly bullish on Regeneron Pharmaceuticals Inc (NASDAQ: REGN and Constellation Pharmaceuticals Inc (NASDAQ: CNST ). The Regeneron, Constellation Analysts: Analyst Matthew Luchini upgraded Regeneron from Neutral to Outperform and maintained the price target at $630. Analyst Do Kim upgraded Constellation shares from Market Perform to Outperform and increased the price target from $27 to $50. The Regeneron Thesis: The potential exists for continued strong performance from Regeneron's retinal disorder treatment Eylea, the dermatitis and asthma drug Dupixent and the advanced cutaneous squamous cell carcinoma treatment Libtayo, Luchini said in the upgrade note. Additional opportunities are available in the form of ongoing Dupixent label expansion efforts and … Full story available on Benzinga.com
   Brookline Capital Markets Stick to Their Buy Rating for Constellation Pharmaceuticals By Investing.com  2021/02/27 17:55:00 Investing.com
Brookline Capital Markets Stick to Their Buy Rating for Constellation Pharmaceuticals
   Insider Selling: Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) CFO Sells $235,376.00 in Stock  2021/02/26 10:54:49 Watchlist News
Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) CFO Emma Reeve sold 6,260 shares of the stock in a transaction on Monday, February 22nd. The shares were sold at an average price of $37.60, for a total transaction of $235,376.00. Following the completion of the sale, the chief financial officer now directly owns 4,010 shares of the company’s stock, […]
   RBC Capital Stick to Their Buy Rating for Constellation Pharmaceuticals By Investing.com  2021/02/26 01:47:19 Investing.com
RBC Capital Stick to Their Buy Rating for Constellation Pharmaceuticals
   H.C. Wainwright Stick to Their Buy Rating for Constellation Pharmaceuticals By Investing.com  2021/02/25 11:38:21 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Constellation Pharmaceuticals
   Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation  2021/01/25 17:32:58 Benzinga
After strong performance in 2020, biopharma stocks are expected to continue their winning run in the new year. Among the companies in the space, analysts at BMO Capital Markets are particularly bullish on Regeneron Pharmaceuticals Inc (NASDAQ: REGN and Constellation Pharmaceuticals Inc (NASDAQ: CNST ). The Regeneron, Constellation Analysts: Analyst Matthew Luchini upgraded Regeneron from Neutral to Outperform and maintained the price target at $630. Analyst Do Kim upgraded Constellation shares from Market Perform to Outperform and increased the price target from $27 to $50. The Regeneron Thesis: The potential exists for continued strong performance from Regeneron's retinal disorder treatment Eylea, the dermatitis and asthma drug Dupixent and the advanced cutaneous squamous cell carcinoma treatment Libtayo, Luchini said in the upgrade note. Additional opportunities are available in the form of ongoing Dupixent label expansion efforts and … Full story available on Benzinga.com
   Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation  2021/01/25 17:32:58 Benzinga
After strong performance in 2020, biopharma stocks are expected to continue their winning run in the new year. Among the companies in the space, analysts at BMO Capital Markets are particularly bullish on Regeneron Pharmaceuticals Inc (NASDAQ: REGN and Constellation Pharmaceuticals Inc (NASDAQ: CNST ). The Regeneron, Constellation Analysts: Analyst Matthew Luchini upgraded Regeneron from Neutral to Outperform and maintained the price target at $630. Analyst Do Kim upgraded Constellation shares from Market Perform to Outperform and increased the price target from $27 to $50. The Regeneron Thesis: The potential exists for continued strong performance from Regeneron's retinal disorder treatment Eylea, the dermatitis and asthma drug Dupixent and the advanced cutaneous squamous cell carcinoma treatment Libtayo, Luchini said in the upgrade note. Additional opportunities are available in the form of ongoing Dupixent label expansion efforts and … Full story available on Benzinga.com
   Brookline Capital Markets Stick to Their Buy Rating for Constellation Pharmaceuticals  2021/01/04 12:15:00 Investing.com
Brookline Capital Markets Stick to Their Buy Rating for Constellation Pharmaceuticals
   STAT+: Constellation’s blood cancer drug shows greater benefit, easing concerns about its future  2020/12/06 18:12:22 STAT News
More patients and an improved response rate might once again shift the sentiment on Constellation Pharmaceuticals and its contentious drug for myelofibrosis — this time in a positive direction.
   Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock  2020/06/17 00:27:28 GlobeNewswire
CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company…
   Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock | MarketScreener  2020/06/15 20:02:02 MarketScreener
CAMBRIDGE, Mass., June 15, 2020 -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel… | June 15, 2020

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コンステレ―ション・ファ―マシュ―ティカルズ CNST Constellation Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)